Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

BGV1

Financiado

Cerrado

New vaccine for a paradigm shift in Brucellosis

Brucellosis is consistently ranked as the world’s most common and widespread zoonotic disease, meaning that it normally exists in animals but it can also infect humans. In livestock, it causes devastating production losses in low-... ver más

31/05/2019

BRUCELLA GREEN VAC

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

BRUCELLA GREEN VAC No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 1M€

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-05-31

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 5 años

0% 70% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

BRUCELLA GREEN VAC

50.00K€ | Lider

LABEL GRUP DESARROLLO DE LA...

443.10K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 6 meses Fecha Inicio: 2018-11-15
Fecha Fin: 2019-05-31

Líder del proyecto

BRUCELLA GREEN VAC No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 1M€

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Brucellosis is consistently ranked as the world’s most common and widespread zoonotic disease, meaning that it normally exists in animals but it can also infect humans. In livestock, it causes devastating production losses in low-income countries accounting in more than €3bn per year. In humans, there are 500,000 new cases annually requiring long-term hospital treatments. Brucellosis is endemic in most Asia, Africa and LATAM and is prevalent in the EU Mediterranean regions. Also, outbreaks may take place anywhere in a global world with international trading, people travelling all around the world and potential threat of bioterrorism. Since human vaccines are not available, the most rational approach for preventing human brucellosis is the control and eradication of infection in animals. Animal vaccines are an essential tool, but existing vaccines own some inconveniences, such as residual virulence, complex management systems and costly diagnostic techniques that are not appropriate for developing countries; in Europe, control programs are based in tests for animal check-ups and compensation to farmers for slaughter of the infected animals, with vaccination prohibited or highly restricted to areas with higher prevalence of Brucellosis. These inconveniences recommended the development of new candidate vaccines. We are developing BGV1, a patented vaccine that has the potential of allowing, for the first time, mass vaccination of any animal at any time (including pregnant and lactating animals), which is a radical paradigm shift in Brucellosis control and eradication. It also simplifies existing vaccine management systems as it can be used without interfering standard diagnostic techniques. In our 5-year forecast, we estimate accumulated revenue and net profits of €58.29m and €15.13m, a conservative projection by just reaching 86.02m animals that represent only 3.92% of our TAM, generating 1.76bn economic benefits to our users.

Conecta tu I+D

Entra hoy

Forgot your password?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores